Hypothesis: New PCSK9 Inhibitors May Impact Calcific Aortic Valve Disease

作者：Wang, Wenguang; Liu, Chao; Cong, Hongliang^*

来源：Journal of Cardiovascular Pharmacology and Therapeutics, 2017, 22(1): 56-64.

DOI：10.1177/1074248416651721

• calcific aortic valve disease
• proprotein convertase subtilisin/kexin type 9
• dyslipidemia
• lipoprotein(a)
• atherosclerotic cardiovascular disease

Calcific aortic valve disease (CAVD) is a common cardiovascular disease in the elderly individuals associated with major morbidity and mortality. The process is characterized by multiple steps: lipid infiltration, inflammation, fibrosis, and calcification. Inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) represent a new therapeutic category of drugs for the treatment of dyslipidemia and atherosclerotic cardiovascular disease. Monoclonal antibodies of PCSK9 can result in substantial reductions in atherogenic lipoprotein cholesterol-carrying particles, especially lipoprotein(a), and thereby hold the potential for further reducing events associated with atherosclerotic cardiovascular disease. In this article, we reviewed the clinical and experimental studies in order to find the evidence of the involvement of PCSK9 in CAVD and the potential benefits of PCSK9 monoclonal antibodies in clinical therapeutics.

• 出版日期2017-1
• 单位天津医科大学; 天津市胸科医院